On November 19, 2024, Matthew Gall, Chief Financial Officer of ITeos Therapeutics Inc, purchased 5,000 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now holds a total of 65,429 shares in ITeos Therapeutics Inc (ITOS, Financial).
ITeos Therapeutics Inc is a biotechnology company focused on the discovery and development of immuno-oncology therapeutics for patients. The company aims to harness the power of the immune system to provide innovative cancer treatments.
The recent purchase by the insider is part of a broader trend within the company. Over the past year, Matthew Gall has acquired a total of 5,000 shares, with no shares sold. This aligns with the overall insider transaction history for ITeos Therapeutics Inc, which shows 1 insider buy and 0 insider sells over the same period.
On the day of the purchase, shares of ITeos Therapeutics Inc were trading at $7.73 each, resulting in a market cap of $288.618 million. Investors may consider this insider buying activity as a potential indicator of confidence in the company's future prospects.
For further insights into the valuation of ITeos Therapeutics Inc, investors can explore metrics such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
